AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Obesity disorder: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Low-Dose Leptin and the Formerly-ObeseNCT00073242 · results posted 2026-10-27 · National Institute of Diabetes and Digestive and … · 31 people · tests Leptin, Dietary modification, T3 repletion Semaglutide 2.4 mg in Patients With Poor Weight-lossNCT05073835 · results posted 2026-10-26 · University College, London · 70 people · tests Semaglutide 3 mg, Placebo SGLT2 Inhibitor Therapy in Cystic Fibrosis-related DiabetesNCT06149793 · results posted 2026-09-21 · University of Minnesota · 8 people · tests Empagliflozin, Placebo Control A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · results posted 2026-09-04 · Eli Lilly and Company · 1613 people · tests Orforglipron, Placebo Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)NCT04605081 · results posted 2026-08-26 · Yale University · 24 people · tests Naltrexone and Bupropion (NB) medication, Placebo Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)NCT04599478 · results posted 2026-08-26 · Yale University · 92 people · tests Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · results posted 2026-08-14 · Eli Lilly and Company · 3127 people · tests Orforglipron, Placebo Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With ObesityNCT05132088 · results posted 2026-08-14 · Novo Nordisk A/S · 201 people · tests semaglutide 50 mg, placebo (semaglutide) Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)NCT04599504 · results posted 2026-08-06 · Yale University · 16 people · tests Lisdexamfetamine Dimesylate (Medication), Placebo A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380 · results posted 2026-07-20 · Eli Lilly and Company · 238 people · tests Orforglipron, Placebo A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · results posted 2026-05-29 · Rhythm Pharmaceuticals, Inc. · 143 people · tests Setmelanotide, Placebo A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight RangeNCT06041217 · results posted 2026-05-18 · Novo Nordisk A/S · 242 people · tests Semaglutide, Placebo
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow obesity disorder and get a note on your phone with the new trials and papers.

🔔 Follow obesity disorder
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy